GRANULES.NSE · Granules India Limited

-

Please sign in to comment on GRANULES.NSE

1 Comment

Admin

4 years, 1 month ago

Granules India Limited is currently in a long term downtrend where the price is trading 2.1% below its 200 day moving average.

From a valuation standpoint, the stock is 45.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.6.

Granules India Limited's total revenue rose by 20.0% to $8B since the same quarter in the previous year.

Its net income has increased by 129.3% to $1B since the same quarter in the previous year.

Finally, its free cash flow fell by 13.5% to $2B since the same quarter in the previous year.

Based on the above factors, Granules India Limited gets an overall score of 3/5.

Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Exchange	NSE
CurrencyCode	INR
ISIN	INE101D01020

Market Cap	116B
Dividend Yield	0.3%
PE Ratio	23.3
Beta	0.17
Target Price	633.75

ABOUT

Granules India Limited

Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationlly. The company's APIs in various therapeutic categories include anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors. It also offers tablets, caplets, and press-fit capsules in bulk, blister packs, and bottles; high potent products; and other products for oncology. In addition, the company provides development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives. Granules India Limited was founded in 1984 and is based in Hyderabad, India.

GRANULES.NSE · Granules India Limited

-

Granules India Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Granules India Limited using a moving average strategy